Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.
Approximately half of patients with heart failure in the community have HFpEF. Most patients with HFpEF are overweight or obese, and growing evidence suggests that obesity and excess adiposity are not simply comorbidities, but may play a pivotal role in the development and progression of HFpEF.
Patients with obesity-related HFpEF have an especially high burden of debilitating symptoms (shortness of breath, exertional intolerance, swelling/edema) and physical limitations, which collectively result in a poor quality of life. Few treatment options are available, and there are no approved therapies specifically targeting the obesity phenotype of HFpEF.
Read the full article at news-medical.net